This statement outlines how the International Alliance of Dermatology Patient Organizations (GlobalSkin) works with partners who provide funding to support the implementation of our annual activities and initiatives.
It is important to note that GlobalSkin is an alliance of patient organizations around the world that are working to improve the lives of people who live with dermatological conditions. Our activities are focused in three main areas: support of our Members, advocacy and raising awareness of the impact of dermatological diseases, and research.
A written agreement between the funder and GlobalSkin outlining the nature and amount of the funding and the period covered is required before GlobalSkin will accept funding from any source. The funding sources are acknowledged with thanks on relevant publications linked to an event/initiative on our website.
In Fiscal Year 2025, GlobalSkin was 100% funded by industry and received sponsorship from 21 companies:
- AbbVie
- Almirall
- Amgen
- Beiersdorf
- Boehringer Ingelheim
- Chiesi
- Eli Lilly & Co
- Fondation Eczema
- Incyte
- Kyowa Kirin
- L'Oreal
- La Roche-Posay
- Novartis
- Pfizer
- Pierre Fabre
- Regeneron
- Roche
- Sanofi
- Takeda
- UCB
- Viatris
None of these companies provided 25% or more of GlobalSkin’s funding. The Sanofi/Regeneron alliance partnership provided the highest percentage at 11.9%.
GlobalSkin’s revenues were also comprised of thought leadership income (1.3%).
Principles for Industry Support
In order to safeguard its values and those of its members, and to assure the independence of the patient voice in all its affairs, GlobalSkin adheres to the Consensus Framework for Ethical Collaboration.
Derived from the individual codes of ethical practice and health policy positions of the supporting organizations, this Consensus Framework is based on four overarching principles:
- Putting patients first
- Supporting ethical research and innovation
- Ensuring independence and ethical conduct
- Promoting transparency and accountability